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ER stress arm XBP1s plays a pivotal role in
proteasome inhibition-induced bone
formation
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Yanmeng Wang1,2, Lei Lei1, Baiyan Wang5, Ramone A. Williamson1, Andrew Chantry4, Pengcheng He6, Ang Li7,
Hendrik De Raeve8, Karin Vanderkerken2, Aili He5 and Jinsong Hu1*
Abstract
Background: Bone destruction is a hallmark of multiple myeloma (MM). It has been reported that proteasome
inhibitors (PIs) can reduce bone resorption and increase bone formation in MM patients, but the underlying
mechanisms remain unclear.
Methods: Mesenchymal stem cells (MSCs) were treated with various doses of PIs, and the effects of bortezomib or
carfilzomib on endoplasmic reticulum (ER) stress signaling pathways were analyzed by western blotting and real-
time PCR. Alizarin red S (ARS) and alkaline phosphatase (ALP) staining were used to determine the osteogenic
differentiation in vitro. Specific inhibitors targeting different ER stress signaling and a Tet-on inducible
overexpressing system were used to validate the roles of key ER stress components in regulating osteogenic
differentiation of MSCs. Chromatin immunoprecipitation (ChIP) assay was used to evaluate transcription factor-
promoter interaction. MicroCT was applied to measure the microarchitecture of bone in model mice in vivo.
Results: We found that both PERK-ATF4 and IRE1α-XBP1s ER stress branches are activated during PI-induced
osteogenic differentiation. Inhibition of ATF4 or XBP1s signaling can significantly impair PI-induced osteogenic
differentiation. Furthermore, we demonstrated that XBP1s can transcriptionally upregulate ATF4 expression and
overexpressing XBP1s can induce the expression of ATF4 and other osteogenic differentiation-related genes and
therefore drive osteoblast differentiation. MicroCT analysis further demonstrated that inhibition of XBP1s can
strikingly abolish bortezomib-induced bone formation in mouse.
Conclusions: These results demonstrated that XBP1s is a master regulator of PI-induced osteoblast differentiation.
Activation of IRE1α-XBP1s ER stress signaling can promote osteogenesis, thus providing a novel strategy for the
treatment of myeloma bone disease.
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Introduction
Multiple myeloma (MM) is a hematological malignancy
characterized by the accumulation of clonal plasma cells
in the bone marrow and excessive monoclonal immuno-
globulin in the serum and urine [1]. Osteolytic bone dis-
ease is one of the most debilitating manifestations of
MM. Myeloma bone disease (MBD) is the result of in-
creased destruction of bone and is present in approxi-
mately 80% of newly diagnosed MM patients. Patients
with MBD develop skeletal complications, including dif-
fuse osteopenia, bone pain, pathological fractures, spinal
cord compression, and hypercalcemia, which are signifi-
cant causes of morbidity and mortality, thus severely af-
fecting the quality of patients’ life and survival [2]. The
development of MBD is associated with unbalanced
bone remodeling, in which suppressed osteoblast activity
and increased osteoclast activity result in promoted bone
absorption and impaired new formation [3].
The treatment of MM has changed dramatically in the
last decade. The introduction of new therapeutic drugs,
including proteasome inhibitors (PIs), immunomodula-
tory agents, histone deacetylase inhibitors, and monoclo-
nal antibodies, have significantly improved the overall
survival of MM patients [2, 4]. Among these new drugs,
PIs are the most important classes of agents, and three
kinds of PIs, bortezomib, carfilzomib, and ixazomib,
have been approved for the treatment of MM. Bortezo-
mib is the first-in-class PI, which chemically binds re-
versibly to the β5 subunit of the proteasome (PSMB5).
In contrast to bortezomib, carfilzomib is second-in-class
PI, which selectively and irreversibly binds and inhibits
PSMB5. Ixazomib is the first oral PI still selectively and
reversibly targeting PSMB5. Notably, targeting prote-
asome has been implicated in inhibiting bone resorption
and promoting bone formation [5–11]. However, to
date, it is still unclear as to how proteasome inhibitors
directly regulate bone formation.
The endoplasmic reticulum (ER) is an organelle that
serves many general functions, including protein synthe-
sis and transport, protein folding, lipid and steroid syn-
thesis, and carbohydrate metabolism. Perturbations of
ER function may lead to ER stress, which is a central
hub of the cross-compartmental signaling network de-
signed to restore intracellular homeostasis [12]. The ER
stress is distinguished by the action of three main path-
ways, namely IRE1α (inositol-requiring protein 1α)-
XBP1 (X box binding protein 1), PERK (PKR-like ER
kinase)-ATF4 (activating transcription factor 4), and
ATF6 (activating transcription factor 6). Upon activa-
tion, downstream XBP1, ATF4, and ATF6α transcription
factors are translocated to the nucleus where they tran-
scriptionally regulate the expression of target genes [12].
In this regard, recent studies in MM cells revealed that
PI-induced anti-tumor effect is tightly associated with
the activation of ER stress, which triggers the expression
of fatal pro-apoptotic factors [13].
In this study, we aimed to delineate the mechanisms
of PI-induced bone formation. We hypothesize that pro-
teasome inhibition-activated ER stress signaling is tightly
involved in the osteoblast differentiation. To test this hy-
pothesis, we first compared the effects of bortezomib
and carfilzomib on osteogenesis of normal mouse bone
marrow mesenchymal stem cells (mMSCs), MM patient-
derived mesenchymal stem cells (MM-MSCs), and an
osteoblast precursor cell line MC3T3-E1. Focusing on
the changes and the roles of ER stress signaling path-
ways, we further demonstrated that the activation of the




Bortezomib and carfilzomib were bought from LC La-
boratories (Woburn, MA, USA). For in vitro studies, the
drugs were reconstituted in dimethylsulfoxide at a stock
concentration of 10 mM. PERK inhibitor GSK2606414
was bought from MedChemExpress (Monmouth Junc-
tion, NJ, USA), and IRE1α inhibitor MKC3946 was
bought from BOC Sciences. MKC3946 was diluted in
Cremophor EL (Sigma-Aldrich, Bornem, Belgium) and
PBS to the appropriate concentration.
Cells and cell culture conditions
Mouse bone marrow mesenchymal stem cells were iso-
lated from 4 to 6 weeks aged C57BL/6 mice. The mice
were housed and treated following conditions approved
by the Ethical Committee for Animal Experiments of
Xi’an Jiaotong University Health Science Center (No.
2015-123). Details of isolation and expansion of mMSCs
are specified in Supplemental Method 1. MSCs derived
from MM patients were obtained from the BM samples,
cultured and identified following a protocol previously
described [14]. MC3T3-E1 cell line was obtained from
the Kunming Cell Bank of Type Culture Collection of
the Chinese Academy of Sciences. MSCs and MC3T3-
E1 cells were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% fetal bovine
serum (FBS) (Biological Industries, Kibbutz Beit-
Haemek, Israel) and 100 U/mL penicillin-streptomycin
and 2mM L-glutamine. Cells cultured in an osteogenic
induction media containing 50mg/mL ascorbic acid,
100 nM dexamethasone, and 10mM β-glycerophosphate
sodium were used as positive controls.
Alizarin red S staining
Alizarin red S (ARS) staining was used to examine the
formation of mineralized bone nodules in the various
MSC cultures, following a protocol previously described
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[11]. Images of ARS were captured by using a digital
camera (Nikon D200, Tokyo, Japan) or under a phase-
contrast microscope (Nikon Eclipse TS100, Tokyo,
Japan).
Alkaline phosphatase activity staining in vitro
The Gomori method was used to stain alkaline phos-
phatase (ALP), following the manufacturer’s instructions
(Heart Biotech, Shaanxi, China). Briefly, cells were fixed
with cold isopropanol for 10 min, followed by washing
with ultrapure water. The cells were then stained with
fresh ALP incubation buffer (2% barbitone sodium, 2%
anhydrous calcium chloride, 3% β-sodium glycerol-
phosphate, 2% magnesium sulfate, pH 9.4) for 4 h at
37 °C. The cells were rinsed with ultrapure water for 10
min, treated with 2% cobalt nitrate for 5 min, followed
by 1% ammonium sulfide solution for 2 min. After dry-
ing, the stained cells were imaged by using a digital
camera.
Western blotting
The cells were harvested and lysed with radioimmuno-
precipitation assay (RIPA) buffer containing protease in-
hibitor cocktail and phosphatase inhibitor cocktails
(Sigma-Aldrich, Shanghai, China). Cell lysates were then
subjected to sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE), transferred to polyvinyli-
dene difluoride (PVDF) membranes, immunoblotted
with various antibodies, and analyzed as described previ-
ously [15]. The antibodies and dilutions used for West-
ern blotting are listed in Supplemental Table 1.
RNA extraction, reverse transcription, and quantitative
real-time PCR
RNA extraction, reverse transcription PCR, and real-
time PCR were performed as described previously [15].
The relative expression levels of each gene were analyzed
using the 2−ΔΔCt method. The sequences of forward and
reverse primers for these genes are listed in Supplemen-
tal Table 2.
RT-PCR for Xbp1 splicing assay
A standard RT-PCR analysis was performed to detect
spliced Xbp1 for mouse using the following primers: 5′-
ACACGCTTGGGAATGGACAC-3′ (forward) and 5′-
CCATGGGAAGATGTTCTGGG-3′ (reverse); for hu-
man: 5′-TTGCTGAAGAGGAGGCGGAAG-3′ (for-
ward) and 5′-GGTCCAAGTTGTCCAGAATGC-3′
(reverse). The program was used as follows: (i) 94 °C for
3 min; (ii) 30 cycles of 94 °C for 30 s, 58 °C for 30 s, and
72 °C for 30 s; and (iii) 72 °C for 10 min. The PCR prod-
ucts were separated by 3.5% agarose gel electrophoresis
to resolve the 152 bp (unspliced) and 126 bp (spliced)
amplicons for mouse Xbp1 and 184 bp (unspliced) and
210 bp (spliced) for human XBP1.
Chromatin immunoprecipitation (ChIP) assay
A ChIP assay was performed according to the Simple
ChIP Enzymatic Chromatin IP Kit protocol (Cell Signal-
ing Technology, Shanghai, China) [15]. Briefly, mMSCs
were cultured in the presence of 2.5 nM bortezomib for
1 day. After incubation, cells (1 × 107) were subjected to
the ChIP assay. The chromatin was immunoprecipitated
with anti-XBP1 (Santa Cruz Biotechnology, Dallas, TX,
USA) at a 1:50 dilution and normal mouse IgG (Santa
Cruz Biotechnology, USA) at a 1:100 dilution at 4 °C on
a rotator for 16 h. The fraction of the purified ChIP
DNA or input was used as templates for PCR analysis.
PCR primer pair was generated to detect DNA segments
located at the promoter of mouse Atf4. The nucleotide
sequences of the primers used in the assay are presented
in Supplemental Table 3.
Lentiviral particle transduction
Full-length human XBP1s cDNA was amplified and
cloned into the Tet-On inducible lentiviral vector
GV437 (TetIIP-MCS-EGFP-3FLAG-Ubi-TetR-IRES-
Puromycin) (Genechem, Shanghai, China), and the con-
struct sequence was verified by sequencing. Lentiviral
particles were produced by standard transient transfec-
tion of a three-plasmid system into producer cells 293T.
For lentiviral infection, mMSCs or MC3T3-E1 cells were
seeded overnight; then, the viral particles were added to
the plated cells at a multiplicity of infection of 100 in a
minimal volume of medium supplemented with 5 μg/mL
polybrene for 24 h in order to achieve high transduction
efficiency (> 80%), which can be evaluated by monitoring
GFP expression in living cells. 2.5 μg/mL of doxycycline
was used to induce XBP1s expression for the time indi-
cated. Empty lentiviral vector was used as control.
Mice and treatment schedule
Five-week old C57BL/KaLwRij mice (Envigo, Horst, the
Netherlands) were housed and maintained following the
conditions approved by the Ethical Committee for Ani-
mal Experiments, Vrije Universiteit Brussel (license No.
LA1230281, 18-281-3). Naive C57BL/KaLwRij mice were
treated with MKC3946 (100 mg/kg, intraperitoneally,
daily) and/or a low dose of bortezomib (0.3 mg/kg, sub-
cutaneously, daily). After 7 days of treatment, mice were
sacrificed, and one femur per mouse was defleshed and
stored at 70% EtOH for micro-computed tomography
(microCT) analysis. A second femur was fixed in zinc
fixative for 48 h, decalcified for 48 h, and paraffin-
embedded.
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MicroCT analysis
The fixed femurs isolated from the treated and untreated
mice were scanned using a SkyScan 1272 microCT (Bru-
ker, Belgium). MicroCT analysis was performed as previ-
ously described [16].
Immunohistochemical staining of ALP in bone section
A standard protocol was used for the immunohisto-
chemical staining of ALP in bone section according to
the manufacturer’s instructions (DAKO Envision+ stain-
ing kit, Via Real Carpinteria, CA, USA). Antibody
against ALP (ab203106, Abcam, Cambridge, CA, USA)
was diluted at 1:300. The chromogenic number of ALP-
positive osteoblasts was counted per square millimeter
(4 × 0.25 mm) paratrabecular with a LEICA DM2000
microscope (× 40 magnification).
Statistical analysis
Results were analyzed with GraphPad Prism 5.0 software
(GraphPad Software Inc., La Jolla, CA, USA). All data
are presented as the mean ± standard error of the mean
(SEM). An unpaired t test was used to compare the
mean between two independent groups. A one-way
ANOVA was used to compare the means of more than
two groups. P < 0.05 (*), P < 0.01 (**), P < 0.001 (***), and
P < 0.0001 (****) were considered statistically significant.
Results
Proteasome inhibitors induce osteogenic differentiation
of MSCs and MC3T3-E1 cells
To validate that proteasome inhibition-induced osteo-
genesis is not drug-specific, we compared the effects of
two different proteasome inhibitors bortezomib and car-
filzomib on osteoblast differentiation by performing ARS
and ALP staining. As shown in Fig. 1, we found that low
concentrations of bortezomib and carfilzomib signifi-
cantly and equally induced osteogenic differentiation by
increasing calcium deposition and mineralized bone
nodule formation after 8 days of treatment. Similar re-
sults were also observed in low doses of bortezomib and
carfilzomib-treated MM-MSCs and human normal
MSCs (Supplemental Figure 1). Given to the structurally
and mechanistically difference between bortezomib and
carfilzomib, these findings may strongly suggest that tar-
geting proteasome can trigger osteoblast differentiation.
Moreover, we found that higher concentrations of PIs
are toxic to the cells (Supplemental Figure 2). This is
consistent with previous findings that higher doses of
bortezomib induce pro-apoptotic signaling [8, 17].
Fig. 1 Effects of proteasome inhibitors on osteogenic differentiation of mMSCs, MC3T3-E1 cells, and MM-MSCs. Eighty to 90% confluent mMSCs,
MC3T3-E1 cells, and MM-MSCs in 35-mm dishes were treated with bortezomib (Btz) or carfilzomib (Cfz) at concentrations of 0, 1, and 2.5 nM or
were cultured in osteogenic differentiation medium for 8 days, replacing with fresh medium every 2 days. Alizarin red staining of mMSCs (a),
MC3T3-E1 cells (b), and MM-MSCs (c) treated with bortezomib (upper panel) or carfilzomib (lower panel). Alkaline phosphatase staining of
bortezomib (upper panel) or carfilzomib-treated (lower panel) mMSCs (d), MC3T3-E1 cells (e), and MM-MSCs (f). Images shown are representative
of 3 independent experiments
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Proteasome inhibition induces the expression of key
osteogenic differentiation-related genes and activates ER
stress signaling
Next, we examined the effects of bortezomib on the ex-
pression of osteogenic differentiation-related genes and
found that treatment with bortezomib significantly in-
creased the expression of alpha 1 type 1 collagen
(Col1a1), osteopontin (OPN), and osteocalcin (OCN),
runt-related transcription factor 2 (RUNX2), and bone
morphogenetic protein 2 (BMP2) on the mRNA level
(Fig. 2a). Consistent with these observations, we found
that bortezomib increased the expression of these osteo-
genic differentiation-related genes on the protein level
(Fig. 2b). These findings indicate that bortezomib can
trigger the expression of osteoblastic phenotype-specific
genes to induce osteogenic differentiation.
To ascertain whether ER stress signaling is involved in
proteasome inhibition-mediated osteoblast differentiation,
Fig. 2 Bortezomib induces the expression of osteoblast differentiation-related markers, and activates ER stress signaling branches. Confluent MSCs
or MC3T3-E1 cells were treated with or without bortezomib for 24 h. a Real-time PCR analysis of the expression of Col1a1, Ocn, Opn, Runx2, and
Bmp2 in 2.5 nM of bortezomib-treated and untreated mMSCs (left panel) or MC3T3-E1 cells (right panel). b Western blotting analysis
demonstrating the expression of Col1a1, Ocn, Opn, Runx2, and Bmp2 in bortezomib-treated (0, 1, 2.5 nM) mMSCs (left panel) and MC3T3-E1 cells
(right panel). c Real-time PCR analysis of ER stress markers Grp78, Chop, and Atf4 in 2.5 nM of bortezomib-treated and untreated mMSCs (top
panel), MC3T3-E1 cells (middle panel), and MM-MSCs (bottom panel). d Western blotting analysis of the expression of ER stress signaling in
bortezomib-treated (0, 1, 2.5 nM) mMSCs (left panel) and MC3T3-E1 cells (right panel). e Western blotting analysis of the changes of the
osteogenesis markers and the key components of three major ER stress signaling branches in bortezomib-treated (0, 1, 2.5 nM) MM-MSCs. f RT-
PCR analysis of the splicing of Xbp1 in mMSCs (left panel) and MC3T3-E1 cells (right panel) without or with bortezomib-treated (1 nM). Data
shown are representative of 3 independent experiments (*P < 0.05, **P < 0.01)
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we further investigated the changes of ER stress markers
and the key regulators in response to bortezomib treat-
ment. As shown in Fig. 2c and d, the expression of ER
stress markers Grp78, Chop, and Atf4 were significantly
upregulated by bortezomib on both mRNA and protein
levels, suggesting the activation of ER stress signaling in
bortezomib-treated MSCs and MC3T3-E1 cells. Further-
more, among the three major ER stress signaling path-
ways, we found that bortezomib upregulated the
expression levels of Atf4 and Xbp1s, other than Atf6. Fo-
cusing on the changes of Atf4, we further found that its
upregulation was tightly associated with the enhanced
transcription on the mRNA level. Similar changes on
osteogenic markers and ER stress regulators were also
confirmed in bortezomib-treated MM-MSCs (Fig. 2e) and
human MSCs from healthy donors (Supplemental Fig-
ure 3). Considering that the changes of Xbp1 are regulated
by unconventional mRNA splicing, we used RT-PCR to
amplify the expression of unspliced and spliced Xbp1 and
demonstrated that bortezomib significantly triggered the
splicing of Xbp1 in the three kinds of tested cells (Fig. 2f).
Both ATF4 and XBP1s ER stress signaling pathways are
involved in proteasome inhibition-induced osteogenic
differentiation
To clarify whether the activation of ER stress signaling
branch ATF4 and XBP1s are directly involved in
bortezomib-induced osteogenic differentiation, we next
investigated the underlying mechanisms of each branch
in this process. As shown in Fig. 3a and b, we found that
the bortezomib-induced bone nodule formation was sig-
nificantly impaired when combined with a potent PERK
inhibitor GSK2606414 or IRE1α inhibitor MKC3946. In
addition, we found that the expression of the
bortezomib-induced osteogenic differentiation-related
marker Col1a1, Ocn, Bmp2, and Runx2 were reversed,
whereas the expression of Opn was not changed by
GSK2606414 (Fig. 3c). However, when using IRE1α in-
hibitor MKC3946 to abolish the formation of Xbp1s, we
observed that it significantly decreased the expression of
all these osteoblastic differentiation-related molecules
(Fig. 3d).
XBP1s regulates the activation of PERK-ATF4 ER stress
signaling pathway
To gain further insight into the relationship between
XBP1s and ATF4 in bortezomib-induced osteogenic dif-
ferentiation, we investigated the crosstalk between these
two branches. As shown in Fig. 4a, when using PERK in-
hibitor GSK2606414 to decrease the expression of Atf4,
we observed that it did not affect the expression of
Xbp1s. However, when using IRE1α inhibitor MKC3946
to inhibit the formation of Xbp1s, we observed that it
markedly decreased the expression of Atf4 (Fig. 4b).
Moreover, we validated the effect of MKC3946 on de-
creasing of the bortezomib-induced splicing of Xbp1 by
RT-PCR analysis (Fig. 4c). These data strongly suggest
that ER stress branch Xbp1s could affect the expression
of Atf4. Therefore, we next sought to investigate how
Xbp1s regulates the expression of Atf4. Interestingly, nu-
cleotide sequence analysis revealed that it contains 1
binding site for Xbp1s at the promoter region of Atf4
(Fig. 4d). This finding prompted us to investigate
whether Xbp1s acts as a transcription factor for Atf4. To
test this possibility, we performed ChIP assay using nu-
clear extracts from bortezomib-treated and untreated
mMSCs and a set of primers designed to amplify the
promoter region (− 117 to + 43) of Atf4. As expected,
the PCR amplification of the ChIP assay revealed that
Xbp1s was capable of binding to the Atf4 promoter
(Fig. 4e). These observations indicate that the activation
of Xbp1s can further transcriptionally enhance the ex-
pression of Atf4 in response to bortezomib treatment.
Overexpression of human XBP1s triggers osteogenic
differentiation
To further validate the key role of Xbp1s in osteogenic
differentiation, we used a Tet-On inducible lentiviral
vector to overexpress human XBP1s in mMSCs and
MC3T3-E1 cells. As shown in Fig. 5a, ARS showed that
forced expression of XBP1s significantly induced bone
nodule formation in mMSCs and MCT3-E1 cells, in
contrast to the empty vector-transduced group. More-
over, in these two groups transduced with XBP1s,
doxycycline-induced higher level of XBP1s expression
was associated with markedly enhanced osteogenic dif-
ferentiation. Consistent with these findings, we also con-
firmed higher ALP activity in the two groups
overexpressing XBP1s (Fig. 5b). In addition, we found
that overexpression of XBP1s could increase the expres-
sion of the osteogenic differentiation-related molecules,
including Col1a1, Ocn, Bmp2, Runx2, and Opn (Fig. 5c).
More importantly, we observed that overexpression of
XBP1s induces a higher level of Atf4, as well as Grp78
and Chop (Fig. 5d).
Inhibition of IRE1α-Xbp1 signaling reverses bortezomib-
induced bone formation in mice
To further determine the indispensable role of Xbp1s in
proteasome inhibition-induced osteoblast differentiation
in vivo, we investigated the effects on new bone forma-
tion in young mice treated with bortezomib in the pres-
ence or absence of the IRE1α inhibitor MKC3946
(Fig. 6a). We demonstrated that bortezomib enhanced
the bone formation in the femur of the treated mice.
Nonetheless, inhibition Xbp1s formation with IRE1α in-
hibitor MKC3946 significantly abolished bortezomib-
mediated bone formation (Fig. 6b). Parametric analysis
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using microCT revealed a significant increase in the
bone volume (bone volume/tissue volume), trabecular
thickness, and trabecular number by bortezomib
(Fig. 6c–e). In contrast, the trabecular separation was de-
creased by bortezomib (Fig. 6f). However, when using
MKC3946 to inhibit Xbp1s signaling in mouse, we ob-
served that bortezomib-enhanced bone volume was sig-
nificantly decreased to the level of the vehicle-treated
control group. Similarly, both trabecular thickness and
trabecular number were also decreased by MKC3946,
but no statistically significant difference was observed.
Simultaneously, the bortezomib-decreased trabecular
separation was increased to the level of the vehicle-
treated control group. Importantly, we observed similar
changes in the number of osteoblasts in the femur by
the combinational treatment with bortezomib and
MKC3946 (Fig. 6g). These data further support that bor-
tezomib can increase bone formation through activation
of the XBP1s pathway in vivo.
Discussion
In this study, we provided both in vitro and in vivo evi-
dence indicating that ER stress sensor XBP1s is a master
regulator of the PI-induced bone formation. PIs can acti-
vate XBP1s in MSCs, which further drives the osteogenic
differentiation, and therefore promotes new bone
formation.
As a common and devastating complication of MM,
MBD is characterized by osteolytic destruction that
results from uncoupled or severely imbalanced bone
remodeling with increased osteoclast activity and
suppresses osteoblast function [2]. Currently, bisphosphonates
Fig. 3 Inhibition of Atf4 and Xbp1s ER stress arms impairs bortezomib-induced osteogenic differentiation. Alizarin red staining shows the effects
of GSK2606414 (a) or MKC3946 (b) on bortezomib-induced osteogenic differentiation in mMSCs (upper panel) and MC3T3-E1 (lower panel) cells.
Eighty to 90% confluent MSCs or MC3T3-E1 cells in 35-mm dishes were treated without or with bortezomib (1 nM) in the absence or presence of
the PERK inhibitor GSK2606414 (2.5 nM) or IRE1α inhibitor MKC3946 (10 nM) for 8 days. The culture medium was refreshed every 2 days. The
images were taken on a Nikon Eclipse TS100 microscope (scale bars represent 50 μM). c, d Western blotting analysis of the effects of GSK2606414
or MKC3946 on bortezomib-induced osteogenic differentiation-related markers in mMSCs (left panel) and MC3T3-E1 cells (right panel). Confluent
MSCs or MC3T3-E1 cells were treated without or with bortezomib (1 nM) in the absence or presence of the PERK inhibitor GSK2606414 (2.5 nM)
or IRE1α inhibitor MKC3946 (10 nM) for 24 h. Data shown are representative of 3 independent experiments
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are the only pharmacological agents recommended for
the treatment and prevention of MBD [18]. As
pyrophosphate analogs, bisphosphonates bind to
hydroxyapatite crystals and are incorporated into the
exposed bone areas. During bone remodeling, bispho-
sphonates are absorbed by osteoclasts and lead to in-
hibition of osteoclast activity and the induction of
apoptosis. Both preclinical and clinical data have
demonstrated that PIs also show a striking bone pro-
tection benefit in patients with MM. Due to the high
apoptotic sensitivity of MM cells to proteasome inhib-
ition, PI-induced bone protection is considered to be
associated with the reduced tumor burden and the
inhibited osteoclast formation and activity [9, 19, 20].
Nonetheless, emerging data also indicate that prote-
asome inhibition may play a critical role in the regu-
lation of osteoblast differentiation. Several different
groups have demonstrated that PI-induced bone pro-
tection is tightly related to the increased number or
activity of osteoblasts in MM [8, 9, 21–23], but the
underlying molecular mechanisms remain poorly
understood.
The ubiquitin-proteasome system (UPS) is a key regu-
lator of intracellular protein hemostasis, cell cycle con-
trol, metabolism, survival, apoptosis, and elimination of
damaged proteins that are toxic to the cells. The func-
tion of MM cells is more dependent on UPS to degrade
the unfolded/misfolded proteins and functional proteins
accumulated in the ER lumen and cytosol, since it con-
tains a high amount of secreted proteins, including
monoclonal immunoglobulin and various cytokines.
However, when inhibiting the UPS pathway, the accu-
mulation of the unfolded/misfolded proteins and func-
tional proteins in the ER lumen and cytosol will trigger
ER stress and the subsequent ER stress-induced apop-
tosis or resistance [15, 24, 25]. Recent studies revealed
that the mechanisms of action of proteasome inhibition
in MM therapy were related to the activation of ER
stress. ER stress-triggered pro-apoptotic signaling has
emerged gradually to be the main mechanism of indu-
cing MM cell death by PIs, in addition to the inhibition
of NF-κB signaling [13, 24, 26]. Given the importance of
ER in maintaining protein, lipid, and redox homeostasis,
controlling secretory processes, ER stress is an essential
regulatory mechanism that is aimed at allowing cells to
adapt to the changing environment. Correspondingly,
ER stress initiates an intrinsic signaling network, which
consists of PERK-ATF4, IRE1α-XBP1, and ATF6, three
main pathways that lead to major changes in transcrip-
tional programs. As such, ER stress has been implicated
in many aspects of cellular function and dysfunction, in-
cluding survival, proliferation, autophagy, migration, and
differentiation [27, 28].
We speculated that ER stress might be an important
regulator of the bone protection induced by proteasome
inhibitors in MM (Fig. 7). In this regard, Garrett et al.
Fig. 4 Xbp1s regulates the expression of Atf4. a, b Western blotting analysis of the effects of GSK2606414 or MKC3946 on bortezomib-activated
Atf4 and Xbp1s in mMSCs (left panel) and MC3T3-E1 cells (right panel). Confluent MSCs or MC3T3-E1 cells were treated without or with
bortezomib (1 nM) in the absence or presence of the PERK inhibitor GSK2606414 (2.5 nM) or IRE1α inhibitor MKC3946 (10 nM) for 24 h. c RT-PCR
analysis of the effects of MKC3946 on the bortezomib-induced formation of Xbp1s mRNA. MSCs or MC3T3-E1 cells were treated as the
abovementioned. d A schematic of the promoter region of the Atf4 gene. One putative Xbp1s-binding site (white rectangle, − 83/− 80) is shown.
e ChIP assays using control IgG, antibodies against Xbp1s. Cell extracts were collected from mMSCs treated with or without bortezomib (2.5 nM)
for 16 h. Protein/DNA complexes from cells were precipitated without antibody (input) or with an Xbp1s antibody or IgG. PCR was performed
using a set of primers covering the promoter region containing the putative Xbp1s binding site. PCR using input DNA was used as a positive
control. PCR using primers covering the promoter region of the Atf4 gene (− 1218/− 1066) was used as a negative control. Data shown are
representative of 3 independent experiments
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initially found the link between the UPS and bone re-
modeling and showed that selective inhibition of prote-
asome stimulates bone formation in mouse [6].
Thereafter, it was further demonstrated by Mukherjee
et al. that MSCs are the preferential stem/progenitor
population that were induced by bortezomib to differen-
tiate into osteoblasts [29]. In MM, it was further demon-
strated that bortezomib can promote osteoblast activity
in vitro and in vivo [8, 21, 22]. Along these lines, we fur-
ther revealed that targeting proteasome can activate ER
stress signaling in MSCs ongoing osteogenesis. Import-
antly, we found that the activation of both ATF4 and
XBP1s branches were involved in the regulation of PI-
induced osteoblast differentiation. In terms of the ATF4,
it has been implicated in the regulation of osteoblast
biology [30–33]. ATF4 was initially found to transcrip-
tionally regulate the expression of Ocn, which acts in the
bone matrix to regulate mineralization [34]. ATF4 was
also demonstrated to be a critical determinant of bone
mass postnatally and toughness through posttranscrip-
tional mechanisms by upregulating the synthesis of
Col1a1 [31, 32]. As a transcription factor, ATF4 can be
induced by a variety of stress stimuli to regulate
osteoblast differentiation [30, 32, 33, 35–41]. Concerning
the relationship between ATF4 and proteasome inhib-
ition, it has been suggested that bortezomib can activate
ATF4 to affect osteoblast differentiation [11, 17]. In
agreement with previously published data, herein, we
confirmed that proteasome inhibition can regulate
osteogenic differentiation through activating ATF4, and
further demonstrated that proteasome inhibition-
induced ATF4 can affect the expression of osteoblast-
specific genes and the osteoblastic mineralization.
One of the important findings in this study may be the
key role of XBP1s arm of ER stress in proteasome
inhibition-induced osteoblast differentiation. Upon the
induction of ER stress, the activation of the endonucle-
ase activity of IRE1α by dimerization and autophospho-
rylation leads to unconventional splicing of XBP1
mRNA, which will be translated to be an active tran-
scription factor XBP1s [42]. Our observations indicate
that XBP1s arm was activated in response to proteasome
inhibition stimuli on both mRNA and protein levels.
Moreover, when using the IRE1α inhibitor to inactivate
this signaling pathway, we discovered that the reduced
Xbp1s formation strikingly impaired bortezomib-
Fig. 5 Forced expression of XBP1s induces osteoblast differentiation. mMSCs and MC3T3-E1 cells transduced with lentiviral-XBP1s vectors were
cultured in the absence or presence of 2.5 μg/mL of doxycycline to induce a higher level of XBP1s expression. Cells transduced with empty
lentiviral vectors were used as control. a Alizarin red staining of the mineralized nodule in mMSCs and MC3T3-E1 cells overexpressing XBP1s. The
transduced mMSCs and MC3T3-E1 cells were treated with or without doxycycline (Dox) for 5 days and then determined by Alizarin red staining.
Images were viewed by a Nikon Eclipse TS100 microscope (scale bars represent 50 μM). b Alkaline phosphatase staining of the transduced
mMSCs and MC3T3-E1 cells treated with or without doxycycline for 5 days. c Western blotting analysis of the osteogenic markers in mMSCs and
MC3T3-E1 cells overexpressing XBP1s. mMSCs or MC3T3-E1 cells transduced with lentiviral-XBP1s vectors were cultured in the absence or
presence of doxycycline for 24 h. d Western blotting analysis of the expression of XBP1s, Atf4, and ER stress markers in the transduced MSCs and
MC3T3-E1 cells treated by doxycycline for 24 h. Each assay represents a separate experiment carried out in triplicate
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induced mineralization and significantly reduced the ex-
pression of osteogenic differentiation markers in MM-
MSCs (Supplemental Figure 4). In contrast, inhibition of
the ATF4 arm caused nearly but not completely the
osteoblastic mineralization. In addition, we confirmed
that inhibition of Xbp1s can downregulate the expres-
sion of Atf4; conversely, inhibition of ATF4 arm had no
effects on the expression of Xbp1s. In support of this
finding, we overexpressed human XBP1s in mouse
MSCs and demonstrated that XBP1s can trigger osteo-
genic differentiation and bone mineralization. Consist-
ently, we confirmed an increased expression of Atf4 in
this setting. These data strongly indicate a feedback loop
that Xbp1s positively upregulates the expression of Atf4.
To further investigate the regulatory mechanism be-
tween Xbp1s and Atf4, we performed a ChIP assay and
identified a Xbp1s binding motif at the promoter region
of the Atf4 gene. Limited by the difficulty of obtaining
MM-MSCs, the above findings are mainly based on nor-
mal mMSCs and MC3T3-E1 cells. Given to the demon-
strated difference of MM-MSCs from their healthy
counterparts and the potential effects of tumor micro-
environment, it should be very important to further val-
idate the findings in murine MM model in future.
Fig. 6 Inhibition of IRE1α reverses bortezomib-increased bone volume and osteoblast number in mice. a A schematic diagram showing the
treatment protocol. Five-week-old C57BL/KaLwRij mice were treated with vehicle (Veh, n = 3), bortezomib (0.3 mg/kg, n = 5), and bortezomib
combined with MKC3946 (100 mg/kg, n = 3) for 7 consecutive days. On day 8, mice were sacrificed, microCT, and immunohistochemical staining
used to analyze bone parameters. b Three-dimensional reconstructions of microCT scans of the representative femur from vehicle-, bortezomib-,
and bortezomib combined with MKC3946-treated naive mice. c–f MicroCT analysis of the trabecular bone volume [BV/TV (%)] (c), and trabecular
thickness [Tb.Th (/mm2)] (d), trabecular number [Tb.N (/mm)] (e), and trabecular separation [Tb.Sp (μm)] (f) of the femur of mice treated with
vehicle, bortezomib, and bortezomib combined with MKC3946. g Histograms showing osteoblast number [Ob.N/BS (/mm)] in mice treated with
vehicle, bortezomib, and bortezomib combined with MKC3946. Data represent mean ± SEM; ns, no significance; *P < 0.05, **P < 0.01,
***P < 0.001, ****P < 0.0001
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Transcription factor XBP1s is highly conserved and
has been shown to govern various cell-fate decisions, in-
cluding differentiation, metabolism, apoptosis, and drug
resistance [42–46]. Previous studies have linked XBP1s
to adipogenesis, osteoclastogenesis, eosinophil, and
plasma cell differentiation [44, 47–49]. It has been
shown that XBP1s is tightly related to BMP2-induced
osteoblast differentiation of mouse embryonic fibroblasts
through promoting the transcription of Osterix [50],
which is indispensable for bone formation. In the
current study, our in vitro results strongly support a piv-
otal role of XBP1s in proteasome inhibition-induced
osteoblast differentiation of MSCs. To confirm this find-
ing in vivo, we further investigated the role of XBP1s in
regulating bone formation in a mouse model. Histomor-
phometry revealed that the trabecular bone volume as a
proportion of tissue volume (BV/TV, %), trabecular
thickness (Tb.Th, /mm2), and trabecular number (Tb.N,
/mm) were significantly increased in the femurs of
bortezomib-treated young mice. Similarly, the number
of osteoblasts in femurs from bortezomib-treated mice is
also significantly higher than the control group
(Supplemental Figure 5). On the contrary, when the
IRE1α inhibitor MKC3946 was combined with bortezo-
mib, as expected, it reversed the bone structure parame-
ters like BV/TV and the numbers of osteoblast. These
findings further reveal that ER stress signaling XBP1s is
an essential regulator of osteoblast differentiation
in vivo.
Conclusion
In conclusion, the present study revealed that the activa-
tion of ER stress signaling pathway IRE1α-XBP1 is a piv-
otal mediator of proteasome inhibition-induced
osteoblast differentiation. The importance of XBP1s in
proteasome inhibition-induced bone formation relies on
its direct effects on the transcription of osteogenic
differentiation-related genes, and the positive feedback
control of the expression of another ER stress arm
ATF4. Our findings provide evidence for a better under-
standing of the mechanisms of PI-induced bone protec-
tion in MM and provide the impetus for future studies
to investigate XBP1s potential as a target for the preven-
tion and treatment of MBD.
Fig. 7 Schematic diagram depicting the roles of ER stress signaling arm Xbp1s in regulating osteoblast differentiation induced by
proteasome inhibitors
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Supplementary information accompanies this paper at https://doi.org/10.
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Additional file 1: Supplemental Figure 1. Effects of proteasome
inhibitors on osteogenic differentiation of human MSCs. Human bone
marrow mesenchymal stem cells (hMSCs) were obtained from the
femoral head of patients undergoing hip replacement surgery for femoral
head osteonecrosis with informed consent, following a protocol
previously described by De Becker A, et al. (Haematologica 2007; 92(4):
440–449). 80%–90% confluent hMSCs in 35 mm dishes were treated with
bortezomib (Btz) or carfilzomib (Cfz) at concentrations of 0, 1, 2.5 nM, or
were cultured in osteogenic differentiation medium for 8 days, and the
medium was replaced every 2 days. (A) Alizarin red staining of hMSCs
treated with bortezomib (upper panel) or carfilzomib (lower panel). (B)
Alkaline phosphatase staining of bortezomib (upper panel) or carfilzomib-
treated (lower panel) hMSCs. Images shown are representative of 3 inde-
pendent experiments.
Additional file 2: Supplemental Figure 2. Flow cytometry analysis of
the effects of bortezomib on cell apoptosis. mMSCs and MC3T3-E1 cells
were treated with various concentrations of bortezomib for 24 h, then
stained with Annexin V-FITC/7-AAD Apoptosis Detection Kit (#640922,
Biolegend, CA, USA). The samples were analyzed using a BD FACSCanto II
flow cytometer and FlowJo software package V7.6.1 (Tree Star, Inc., OR,
USA). Data are representative of three independent experiments.
Additional file 3: Supplemental Figure 3. Western blotting analysis of
the expression of XBP1s, ATF4, ATF6 and the osteogenic differentiation
markers in bortezomib-treated hMSCs. Confluent hMSCs were treated
with bortezomib (0, 1, 2.5 nM) for 24 h, the cell lysates were then har-
vested for Western blotting analysis.
Additional file 4: Supplemental Figure 4. Realtime PCR analysis of
the expression of osteogenesis markers in MM-MSCs. Confluent MM-
MSCs were treated with vehicle (Veh), MKC3946 (10 nM), bortezomib (Btz,
2.5 nM), and the combination for 24 h, then mRNA was extracted and
Realtime PCR was performed with primers COL1A1, BMP2, OCN (Osteocal-
cin), OPN (Osteopontin), and RUNX2. Data represent mean ± SEM, ns: no
significance, * P < 0.05.
Additional file 5: Supplemental Figure 5. Immunohistochemical
staining of osteogenesisi marker ALP in mouse femur bone paraffin-
embedded sections. (A-C) Representative photomicrographs of the IHC
staining for ALP in the femur bone section from mice treated with ve-
hicle (A), bortezomib (B), or bortezomib combined with MKC3946. Arrows
indicate osteobalsts. Scale bars represent 125 μM.
Additional file 6: Supplemental Method 1.
Additional file 7: Supplemental Table 1. List of antibodies used for
Western blotting.
Additional file 8: Supplemental Table 2. Primer sequences used for
Realtime PCR analysis.
Additional file 9: Supplemental Table 3. Primer sequences used for
ChIP assay.
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